Currently, NBs targeting HER2 [12, 13], prostate specific membrane antigen (PSMA) [14, 15] and cancer antigen 125 (CA-125) [16] have been investigated in vivo for breast, prostate, and ovarian cancer diagnosis, respectively. This evidence concerns the gene FOLH1 and ovarian carcinoma.